Literature DB >> 1940365

Differential stability of antigenic MHC class I-restricted synthetic peptides.

C Widmann1, J L Maryanski, P Romero, G Corradin.   

Abstract

Various synthetic peptides recognized as Ag by CTL in the context of MHC class I molecules were tested for stability in vitro and in vivo. Peptide inactivation in vitro was quantitated by titrating the amount of peptide required to sensitize target cells for lysis by specific CTL clones. The degree of inactivation after overnight incubation at 37 degrees C varied widely among a series of antigenic peptides. Some were nearly unaffected, whereas others lost activity by more than 100-fold or even 10,000-fold. However, no correlation was found between susceptibility to serum inactivation and antigenic potency as measured in short term cytolytic assays. No inactivation occurred at 4 degrees C, or at 37 degrees C in the absence of serum, under the conditions used. Serum inactivation most likely involved proteolysis because it could be inhibited by protease inhibitors. Moreover, presumed cleavage products of a radiolabeled susceptible peptide could be visualized by TLC. In vivo, the persistence of the antigenic activity of the injected peptides, either in extracellular fluids or on tumor target cells growing in an ascites form, correlated with the degree of stability found for the peptides in vitro. The differential stability of synthetic peptides may have important consequences for attempts to manipulate the development of an immune response in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940365

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Skin test to assess virus-specific cytotoxic T-cell activity.

Authors:  T M Kündig; A Althage; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Analysis of the association of peptides of optimal length to class I molecules on the surface of cells.

Authors:  K L Rock; L Rothstein; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

3.  Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules.

Authors:  L D Falo; L J Colarusso; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

4.  Antigen kinetics determines immune reactivity.

Authors:  Pål Johansen; Tazio Storni; Lorna Rettig; Zhiyong Qiu; Ani Der-Sarkissian; Kent A Smith; Vania Manolova; Karl S Lang; Gabriela Senti; Beat Müllhaupt; Tilman Gerlach; Roberto F Speck; Adrian Bot; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

Review 5.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).

Authors:  A A Scalzo; S L Elliott; J Cox; J Gardner; D J Moss; A Suhrbier
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

7.  Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.

Authors:  Lbachir BenMohamed; Alan Thomas; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum.

Authors:  M F Powell; T Stewart; L Otvos; L Urge; F C Gaeta; A Sette; T Arrhenius; D Thomson; K Soda; S M Colon
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  Extracellular processing of peptide antigens that bind class I major histocompatibility molecules.

Authors:  L A Sherman; T A Burke; J A Biggs
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

10.  Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules.

Authors:  S Kozlowski; M Corr; T Takeshita; L F Boyd; C D Pendleton; R N Germain; J A Berzofsky; D H Margulies
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.